Lipoprotein(a) in neoplastic transformation

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-09-07 DOI:10.1016/j.cca.2025.120581

Dan-Qi Han , Tian-Yi Ma , Duo-Hong Wu , Shi-Juan Lu , Jiang-Hua Zhong , Jian-Jun Li

引用次数: 0

Abstract

Cardiovascular diseases and cancer are top global causes of death, sharing risk factors and treatment strategies. Although dyslipidemia is linked to both, its exact roles are unclear. Recent studies suggest a potential association between plasma lipoprotein(a) levels and cancer risk. This review compiles the latest on lipoprotein(a)’s relation to several cancers and explores potential underlying mechanisms, aiming to deepen understanding of its role in cancer.

查看原文本刊更多论文

肿瘤转化中的脂蛋白(a)。

心血管疾病和癌症是全球最主要的死亡原因，它们具有共同的风险因素和治疗策略。尽管血脂异常与两者有关，但其确切作用尚不清楚。最近的研究表明，血浆脂蛋白(a)水平与癌症风险之间存在潜在关联。本文综述了脂蛋白(a)与几种癌症的关系，并探讨了其潜在的机制，旨在加深对其在癌症中的作用的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.